These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37078628)

  • 1. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
    Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
    Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
    Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
    AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
    Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK
    Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
    Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K
    Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
    Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
    J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
    Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
    Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy.
    Cooperberg MR; Freedland SJ; Pasta DJ; Elkin EP; Presti JC; Amling CL; Terris MK; Aronson WJ; Kane CJ; Carroll PR
    Cancer; 2006 Nov; 107(10):2384-91. PubMed ID: 17039503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
    Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
    Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience.
    Leyh-Bannurah SR; Dell'Oglio P; Zaffuto E; Briganti A; Schiffmann J; Pompe RS; Tilki D; Heinzer H; Graefen M; Karakiewicz PI; Budäus L
    Eur Urol Focus; 2019 Jul; 5(4):568-576. PubMed ID: 29129756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    Athanasiou A; Tennstedt P; Wittig A; Huber R; Straub O; Schiess R; Steuber T
    PLoS One; 2021; 16(11):e0259093. PubMed ID: 34767586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
    Shee K; Cowan JE; Washington SL; Shinohara K; Nguyen HG; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2024 Aug; 7(4):838-843. PubMed ID: 38057193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.